β地中海贫血慢病毒基因治疗后感染野生型HIV一例
本文报告一例输血依赖型β地中海贫血患者在接受beti-cel慢病毒基因治疗后确诊野生型HIV感染。基因治疗后3.5至21个月患者停止输血,总血红蛋白和基因治疗来源的血红蛋白AT87Q分别为6.6至9.5 g/dL和2.8至3.8 g/dL;21个月时因HIV-1感染相关贫血恢复输血。启动抗逆转录病毒治疗6个月后血红蛋白恢复,基因治疗3.5年后已13.4个月未输血。
要点
- 慢病毒基因治疗后可区分野生型HIV与载体来源序列
- HIV感染可致基因治疗后贫血并需恢复输血
- 抗逆转录病毒治疗后可恢复基因治疗造血效果
核心结论
- 本例为慢病毒载体基因治疗受者中首次报告野生型HIV感染,显示beti-cel治疗后长期造血持久,且能区分野生型HIV与BB305来源序列。
研究设计与样本
- 病例报告:1例在1/2期研究HGB-204(NCT01745120)中接受beti-cel治疗的输血依赖型β地中海贫血患者,后续确诊野生型HIV感染。
主要发现
- 基因治疗后3.5至21个月停止慢性红细胞输血,总血红蛋白6.6至9.5 g/dL,基因治疗来源HbAT87Q 2.8至3.8 g/dL。
- 基因治疗后21个月因贫血恢复输血,同时确诊HIV-1感染。
- 定量PCR未检出复制 competent 慢病毒,二代测序确认野生型HIV序列。
- 启动抗逆转录病毒治疗6个月后总血红蛋白8.6 g/dL、HbAT87Q 3.6 g/dL。
- 基因治疗3.5年后已13.4个月未输血。
临床怎么用
- 基因治疗后出现贫血加重需鉴别HIV等新发感染并检测载体来源序列。
- HIV感染确诊后应及时启动抗逆转录病毒治疗以恢复基因治疗造血效果。
局限性
- 为单例病例报告,结果不能推广至所有beti-cel治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Betibeglogene autotemcel (beti-cel) gene therapy (GT) for patients with transfusion-dependent β-thalassemia uses autologous CD34+ cells transduced with BB305 lentiviral vector (LVV), which encodes a modified β-globin gene. BB305 LVV also contains select HIV sequences for viral packaging, reverse transcription, and integration. This case report describes a patient successfully treated with beti-cel in a phase 1/2 study (HGB-204; #NCT01745120) and subsequently diagnosed with wild-type (WT) HIV infection. From 3.5 to 21 months postinfusion, the patient stopped chronic red blood cell transfusions; total hemoglobin (Hb) and GT-derived HbAT87Q levels were 6.6 to 9.5 and 2.8 to 3.8 g/dL, respectively. At 21 months postinfusion, the patient resumed transfusions for anemia that coincided with an HIV-1 infection diagnosis. Quantitative polymerase chain reaction assays detected no replication-competent lentivirus. Next-generation sequencing confirmed WT HIV sequences. Six months after starting antiretroviral therapy, total Hb and HbAT87Q levels recovered to 8.6 and 3.6 g/dL, respectively, and 3.5 years postinfusion, 13.4 months had elapsed since the patient's last transfusion. To our knowledge, this is the first report of WT HIV infection in an LVV-based GT recipient and demonstrates persistent long-term hematopoiesis after treatment with beti-cel and the ability to differentiate between WT HIV and BB305-derived sequences.
引用
- Hongeng S, Anurathapan U, Songdej D, et al. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia. Blood Adv. 2021. PMID: 34196676. doi:10.1182/bloodadvances.2020003680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。